Insulin degludec: A novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes

Luigi F. Meneghini, Bresta Miranda-Palma

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The prevalence of diabetes, a chronic disease that currently poses a significant health burden in both developed and developing countries, is expected to increase significantly over the foreseeable future. In Type 1 diabetes, insulin replacement is absolutely imperative; in Type 2 diabetes, many patients will eventually require insulin replacement therapy to compensate for progressive β-cell failure and maintain blood glucose control. Even though currently available insulin analog preparations more closely mimic physiologic insulin needs when compared with neutral protamine Hagedorn insulin, many patients with diabetes still experience unacceptable glycemic control, in part owing to limitations in insulin therapy, such as hypoglycemia risk, weight gain and the need for patients to adjust their lifestyle to their insulin therapy. Insulin degludec, appropriately labeled as an ultra-long-acting basal insulin, promises to achieve similar blood glucose control to currently available preparations (glargine and detemir insulin), with a reduced risk of hypoglycemia and greater flexibility in the day-to-day timing of insulin administration. Greater flexibility in basal insulin administration and/or reducing hypoglycemia risk in insulin-requiring patients with Type 1 or 2 diabetes may facilitate insulin management for patients and physicians.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalExpert Review of Endocrinology and Metabolism
Volume7
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Long-Acting Insulin
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Insulin
Hypoglycemia
Blood Glucose
insulin degludec
Isophane Insulin
Developed Countries
Developing Countries
Weight Gain
Life Style
Chronic Disease
Therapeutics

Keywords

  • A1C
  • basal insulin
  • fasting plasma glucose
  • hypoglycemia
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Insulin degludec : A novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes. / Meneghini, Luigi F.; Miranda-Palma, Bresta.

In: Expert Review of Endocrinology and Metabolism, Vol. 7, No. 1, 01.2012, p. 9-14.

Research output: Contribution to journalArticle

@article{69b1c71fca4e440dbbb6cb9724fce81b,
title = "Insulin degludec: A novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes",
abstract = "The prevalence of diabetes, a chronic disease that currently poses a significant health burden in both developed and developing countries, is expected to increase significantly over the foreseeable future. In Type 1 diabetes, insulin replacement is absolutely imperative; in Type 2 diabetes, many patients will eventually require insulin replacement therapy to compensate for progressive β-cell failure and maintain blood glucose control. Even though currently available insulin analog preparations more closely mimic physiologic insulin needs when compared with neutral protamine Hagedorn insulin, many patients with diabetes still experience unacceptable glycemic control, in part owing to limitations in insulin therapy, such as hypoglycemia risk, weight gain and the need for patients to adjust their lifestyle to their insulin therapy. Insulin degludec, appropriately labeled as an ultra-long-acting basal insulin, promises to achieve similar blood glucose control to currently available preparations (glargine and detemir insulin), with a reduced risk of hypoglycemia and greater flexibility in the day-to-day timing of insulin administration. Greater flexibility in basal insulin administration and/or reducing hypoglycemia risk in insulin-requiring patients with Type 1 or 2 diabetes may facilitate insulin management for patients and physicians.",
keywords = "A1C, basal insulin, fasting plasma glucose, hypoglycemia, Type 1 diabetes, Type 2 diabetes",
author = "Meneghini, {Luigi F.} and Bresta Miranda-Palma",
year = "2012",
month = "1",
doi = "10.1586/eem.11.86",
language = "English (US)",
volume = "7",
pages = "9--14",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Insulin degludec

T2 - A novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes

AU - Meneghini, Luigi F.

AU - Miranda-Palma, Bresta

PY - 2012/1

Y1 - 2012/1

N2 - The prevalence of diabetes, a chronic disease that currently poses a significant health burden in both developed and developing countries, is expected to increase significantly over the foreseeable future. In Type 1 diabetes, insulin replacement is absolutely imperative; in Type 2 diabetes, many patients will eventually require insulin replacement therapy to compensate for progressive β-cell failure and maintain blood glucose control. Even though currently available insulin analog preparations more closely mimic physiologic insulin needs when compared with neutral protamine Hagedorn insulin, many patients with diabetes still experience unacceptable glycemic control, in part owing to limitations in insulin therapy, such as hypoglycemia risk, weight gain and the need for patients to adjust their lifestyle to their insulin therapy. Insulin degludec, appropriately labeled as an ultra-long-acting basal insulin, promises to achieve similar blood glucose control to currently available preparations (glargine and detemir insulin), with a reduced risk of hypoglycemia and greater flexibility in the day-to-day timing of insulin administration. Greater flexibility in basal insulin administration and/or reducing hypoglycemia risk in insulin-requiring patients with Type 1 or 2 diabetes may facilitate insulin management for patients and physicians.

AB - The prevalence of diabetes, a chronic disease that currently poses a significant health burden in both developed and developing countries, is expected to increase significantly over the foreseeable future. In Type 1 diabetes, insulin replacement is absolutely imperative; in Type 2 diabetes, many patients will eventually require insulin replacement therapy to compensate for progressive β-cell failure and maintain blood glucose control. Even though currently available insulin analog preparations more closely mimic physiologic insulin needs when compared with neutral protamine Hagedorn insulin, many patients with diabetes still experience unacceptable glycemic control, in part owing to limitations in insulin therapy, such as hypoglycemia risk, weight gain and the need for patients to adjust their lifestyle to their insulin therapy. Insulin degludec, appropriately labeled as an ultra-long-acting basal insulin, promises to achieve similar blood glucose control to currently available preparations (glargine and detemir insulin), with a reduced risk of hypoglycemia and greater flexibility in the day-to-day timing of insulin administration. Greater flexibility in basal insulin administration and/or reducing hypoglycemia risk in insulin-requiring patients with Type 1 or 2 diabetes may facilitate insulin management for patients and physicians.

KW - A1C

KW - basal insulin

KW - fasting plasma glucose

KW - hypoglycemia

KW - Type 1 diabetes

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=82955205736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955205736&partnerID=8YFLogxK

U2 - 10.1586/eem.11.86

DO - 10.1586/eem.11.86

M3 - Article

C2 - 30736105

AN - SCOPUS:82955205736

VL - 7

SP - 9

EP - 14

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 1

ER -